• Login
    View Item 
    •   HPS Repository Home
    • Embryo Project Encyclopedia
    • Embryo Project Articles
    • View Item
    •   HPS Repository Home
    • Embryo Project Encyclopedia
    • Embryo Project Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    “General Considerations for the Clinical Evaluation of Drugs” (1977), by the United States Food and Drug Administration

    Thumbnail
    View/Open
    LitClinicalEvaluationCM.xhtml (15.83Kb)
    Author
    Meek, Caroline
    Metadata
    Show full item record
    Abstract
    The United States Food and Drug Administration, or FDA, published 'General Considerations for the Clinical Evaluation of Drugs,' in September 1977. The document defined acceptable practices for investigators who studied new drugs. Specifically, the document outlined the common clinical trial methods. Clinical trials are studies to test whether a new drug is safe before doctors can prescribe it to patients. Prior to 1977, the Protection of Human Subjects Rule primarily regulated clinical drug trials, but it did not specify who could and could not be included in clinical trials. In the document, the FDA recommended that anyone who could become pregnant be excluded from early-phase clinical trials to minimize risks to a potential fetus. After the FDA published the document, investigators excluded women from clinical trials. The document ultimately prevented women of reproductive capacity from participating in early phase clinical trials, which affected women’s health research.
    URI
    https://hpsrepository.asu.edu/handle/10776/13131
    Collections
    • Embryo Project Articles

    Browse

    All of HPS RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister
    DSpace software Copyright © 2015  Duraspace
    Contact Us | Send Feedback